LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

LifeMD announced an exclusive co-marketing collaboration with Halozyme's subsidiary Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED, an FDA-approved testosterone auto-injector. The program will launch in July 2026 across 37 states, offering patients virtual clinical evaluation, lab testing, and home delivery of medication at a transparent price of approximately $249 per month, addressing barriers to hypogonadism treatment.